164 related articles for article (PubMed ID: 12788181)
1. The prognostic significance of Gleason Grade in patients treated with permanent prostate brachytherapy.
Potters L; Purrazzella R; Brustein S; Fearn P; Huang D; Leibel SA; Kattan MW
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):749-54. PubMed ID: 12788181
[TBL] [Abstract][Full Text] [Related]
2. Importance of implant dosimetry for patients undergoing prostate brachytherapy.
Potters L; Huang D; Calugaru E; Fearn P; Lee L; Kattan MW
Urology; 2003 Dec; 62(6):1073-7. PubMed ID: 14665358
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of race on biochemical control in patients with localized prostate cancer treated with permanent brachytherapy: multivariate and matched-pair analyses.
Lee LN; Barnswell C; Torre T; Fearn P; Kattan M; Potters L
Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):282-9. PubMed ID: 12023131
[TBL] [Abstract][Full Text] [Related]
4. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
5. The role of external radiotherapy in patients treated with permanent prostate brachytherapy.
Potters L; Fearn P; Kattan M
Prostate Cancer Prostatic Dis; 2002; 5(1):47-53. PubMed ID: 15195130
[TBL] [Abstract][Full Text] [Related]
6. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer.
Potters L; Morgenstern C; Calugaru E; Fearn P; Jassal A; Presser J; Mullen E
J Urol; 2005 May; 173(5):1562-6. PubMed ID: 15821486
[TBL] [Abstract][Full Text] [Related]
7. Isotope selection for patients undergoing prostate brachytherapy.
Cha CM; Potters L; Ashley R; Freeman K; Wang XH; Waldbaum R; Leibel S
Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):391-5. PubMed ID: 10487561
[TBL] [Abstract][Full Text] [Related]
8. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer.
Zelefsky MJ; Hollister T; Raben A; Matthews S; Wallner KE
Int J Radiat Oncol Biol Phys; 2000 Jul; 47(5):1261-6. PubMed ID: 10889379
[TBL] [Abstract][Full Text] [Related]
9. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma.
Ragde H; Elgamal AA; Snow PB; Brandt J; Bartolucci AA; Nadir BS; Korb LJ
Cancer; 1998 Sep; 83(5):989-1001. PubMed ID: 9731904
[TBL] [Abstract][Full Text] [Related]
10. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
Kollmeier MA; Stock RG; Stone N
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
[TBL] [Abstract][Full Text] [Related]
11. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer.
Merrick GS; Butler WM; Galbreath RW; Lief JH
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):41-8. PubMed ID: 11516849
[TBL] [Abstract][Full Text] [Related]
12. Potency after permanent prostate brachytherapy for localized prostate cancer.
Potters L; Torre T; Fearn PA; Leibel SA; Kattan MW
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1235-42. PubMed ID: 11483334
[TBL] [Abstract][Full Text] [Related]
13. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy.
Potters L; Torre T; Ashley R; Leibel S
J Clin Oncol; 2000 Mar; 18(6):1187-92. PubMed ID: 10715287
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive and novel predictive modeling technique using detailed pathology factors in men with localized prostate carcinoma.
Potters L; Purrazzella R; Brustein S; Fearn P; Leibel SA; Kattan MW
Cancer; 2002 Oct; 95(7):1451-6. PubMed ID: 12237913
[TBL] [Abstract][Full Text] [Related]
15. Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer?
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
BJU Int; 2003 Jan; 91(1):23-9. PubMed ID: 12614244
[TBL] [Abstract][Full Text] [Related]
16. Perineural invasion is not predictive of biochemical outcome following prostate brachytherapy.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Cancer J; 2001; 7(5):404-12. PubMed ID: 11693899
[TBL] [Abstract][Full Text] [Related]
17. External radiotherapy and permanent prostate brachytherapy in patients with localized prostate cancer.
Potters L; Fearn P; Kattan MW
Brachytherapy; 2002; 1(1):36-41. PubMed ID: 15062185
[TBL] [Abstract][Full Text] [Related]
18. Analysis of monotherapy prostate brachytherapy in patients with prostate cancer. Initial PSA and Gleason are important for recurrence?
Galego P; Silva FC; Pinheiro LC
Int Braz J Urol; 2015; 41(2):353-9. PubMed ID: 26005979
[TBL] [Abstract][Full Text] [Related]
19. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.
Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD
Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111
[TBL] [Abstract][Full Text] [Related]
20. Primary Gleason grade 4 impact on biochemical recurrence after permanent interstitial brachytherapy in Japanese patients with low- or intermediate-risk prostate cancer.
Uesugi T; Saika T; Edamura K; Nose H; Kobuke M; Ebara S; Abarzua F; Katayama N; Yanai H; Nasu Y; Kumon H
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e219-23. PubMed ID: 21640517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
